GSK Avandia CV Risk Concealment (1999–2010)
Introduction
Avandia (rosiglitazone) is a thiazolidinedione-class diabetes drug approved by the FDA in May 1999. Marketed by GlaxoSmithKline (GSK), it was prescribed to millions of patients with Type 2 diabetes to improve insulin sensitivity. By the mid-2000s it had annual sales exceeding $3 billion. In 2007, a landmark meta-analysis by Cleveland Clinic cardiologist Steven Nissen shook the global diabetes treatment community and triggered one of the largest pharmaceutical fraud investigations in US history.
The Nissen Meta-Analysis (2007)
In May 2007, the New England Journal of Medicine published a meta-analysis by Dr. Steven Nissen and Kathy Wolski that pooled data from 42 randomised clinical trials involving Avandia. The analysis found that rosiglitazone was associated with a statistically significant 43% increase in the risk of myocardial infarction (heart attack) and a 64% increase in cardiovascular death risk (though the latter did not reach conventional statistical significance). The publication triggered immediate regulatory review in both the US and Europe.
The FDA convened an advisory committee in July 2007, which voted that Avandia posed a cardiovascular risk and that stronger warnings were needed, though it did not recommend withdrawal. The European Medicines Agency suspended Avandia in September 2010, effectively ending its sale in Europe.
Senate Finance Committee Investigation
The Senate Finance Committee investigation, led by Senators Max Baucus and Charles Grassley and concluded in February 2010, found that GSK had possessed internal data suggesting Avandia''s cardiovascular risk as early as 1999 — the year of approval. An internal GSK meta-analysis completed in 2006, a year before Nissen''s publication, had reached similar conclusions about elevated myocardial infarction risk. GSK had not submitted this internal analysis to the FDA.
The Senate report characterised GSK''s conduct as a failure to disclose material safety information to regulators. Former GSK CEO Jean-Pierre Garnier and other executives faced questioning in the investigation.
FDA Restrictions and Reversal
In September 2010, the FDA restricted Avandia to patients who had already been taking it and who could not be adequately controlled with other medications — effectively limiting new prescriptions to near-zero. The agency also required a Risk Evaluation and Mitigation Strategy (REMS). In 2013, following a re-analysis of the RECORD trial data, the FDA lifted the restrictions after concluding the cardiovascular risk was lower than previously estimated — a conclusion that itself generated scientific controversy.
The $3 Billion DOJ Settlement
In July 2012, GSK agreed to a $3 billion settlement with the US Department of Justice — at the time the largest criminal and civil healthcare fraud settlement in US history. The settlement covered multiple allegations including: illegal promotion of Avandia for uses not approved by the FDA, failure to disclose safety data on Avandia to the FDA, and kickbacks to physicians. GSK pleaded guilty to criminal misdemeanour charges.
The Avandia-specific component addressed the failure to disclose cardiovascular safety data and the promotion of the drug to physicians in ways that minimised the risk signal.
Verdict
Confirmed. Senate Finance Committee findings, DOJ settlement ($3 billion, 2012), and GSK''s own internal documents confirm that the company possessed cardiovascular risk data that was not disclosed to regulators in a timely manner. The Nissen meta-analysis confirmed the signal that GSK''s internal 2006 analysis had already identified. Millions of diabetes patients were exposed to elevated cardiovascular risk without adequate warning.
Evidence Filters11
Nissen NEJM 2007: 43% elevated myocardial infarction risk
SupportingStrongDr. Steven Nissen and Kathy Wolski's meta-analysis of 42 Avandia clinical trials found a statistically significant 43% increase in MI risk. Published in the New England Journal of Medicine in May 2007, it triggered immediate FDA and European regulatory review.
Senate Finance Committee: GSK had internal 2006 meta-analysis showing same risk
SupportingStrongThe Senate Finance Committee investigation (February 2010) found that GSK had completed an internal meta-analysis in 2006 — a year before Nissen's publication — that identified similar cardiovascular risk signals. GSK did not submit this analysis to the FDA.
GSK possessed CV risk data from 1999 — year of approval
SupportingStrongSenate investigators found evidence that GSK had internal data suggesting cardiovascular concern in Avandia as early as 1999, the year the FDA approved the drug. These concerns were not disclosed to the agency at the time.
FDA restricted Avandia (September 2010)
SupportingStrongThe FDA restricted Avandia in September 2010, limiting it to patients already taking the drug who could not control their diabetes with other available medications. New prescriptions effectively ended. The FDA also required a Risk Evaluation and Mitigation Strategy.
EMA suspended Avandia in Europe (September 2010)
SupportingStrongThe European Medicines Agency suspended the marketing authorisation for rosiglitazone-containing medicines in Europe in September 2010, concluding that the cardiovascular risks outweighed the benefits.
DOJ $3 billion settlement (2012) — then-largest healthcare fraud settlement
SupportingStrongGSK agreed to a $3 billion settlement with the US Department of Justice in July 2012, covering Avandia safety data concealment, unlawful promotion, and kickbacks to physicians. The settlement included criminal misdemeanour guilty pleas and was the largest healthcare fraud settlement in US history at the time.
FDA reversed Avandia restrictions in 2013 after RECORD re-analysis
DebunkingIn 2013, the FDA lifted restrictions on Avandia after a re-analysis of the RECORD trial data by an independent committee found lower cardiovascular risk than earlier estimates. This reversal generated scientific controversy and does not undo the finding of prior non-disclosure.
Rebuttal
The 2013 restrictions reversal reflects a reassessment of the magnitude of risk, not an exoneration of GSK's conduct in failing to disclose its internal 2006 analysis. The non-disclosure to the FDA is documented and was not rebutted by the RECORD re-analysis.
Avandia did improve glycaemic control in Type 2 diabetes
DebunkingWeakAvandia was a genuinely effective drug for improving blood glucose control in Type 2 diabetes patients. Its efficacy as a glucose-lowering agent is not disputed. The controversy is about cardiovascular risk concealment, not the drug's primary pharmacological action.
Rebuttal
Therapeutic efficacy does not justify concealment of safety risk. Patients and physicians needed balanced information about both the glucose benefit and the cardiovascular risk to make informed treatment choices.
Senate Finance Committee Found GSK Suppressed Adverse Data
SupportingStrongA 2010 bipartisan Senate Finance Committee investigation concluded that GlaxoSmithKline possessed internal analyses showing elevated cardiovascular risk from Avandia years before public disclosure. The report documented deliberate strategies to minimise, counter, and suppress publication of unfavourable trial data.
RECORD Trial Partially Redeemed Avandia's Safety Profile
DebunkingThe RECORD randomised controlled trial (2009, New England Journal of Medicine) found no statistically significant increase in cardiovascular death or myocardial infarction compared to standard therapy. FDA reviewers cited RECORD as evidence that initial meta-analysis risk estimates were overstated, complicating a simple suppression narrative.
Show 1 more evidence point
FDA Advisory Panel Vote Reflected Genuine Scientific Uncertainty
NeutralIn 2010 an FDA advisory panel voted 20-12 that Avandia should remain available with restrictions rather than be withdrawn entirely, reflecting contested evidence rather than clear-cut harm. The split vote indicates legitimate scientific disagreement rather than pure regulatory capture.
Evidence Cited by Believers7
Nissen NEJM 2007: 43% elevated myocardial infarction risk
SupportingStrongDr. Steven Nissen and Kathy Wolski's meta-analysis of 42 Avandia clinical trials found a statistically significant 43% increase in MI risk. Published in the New England Journal of Medicine in May 2007, it triggered immediate FDA and European regulatory review.
Senate Finance Committee: GSK had internal 2006 meta-analysis showing same risk
SupportingStrongThe Senate Finance Committee investigation (February 2010) found that GSK had completed an internal meta-analysis in 2006 — a year before Nissen's publication — that identified similar cardiovascular risk signals. GSK did not submit this analysis to the FDA.
GSK possessed CV risk data from 1999 — year of approval
SupportingStrongSenate investigators found evidence that GSK had internal data suggesting cardiovascular concern in Avandia as early as 1999, the year the FDA approved the drug. These concerns were not disclosed to the agency at the time.
FDA restricted Avandia (September 2010)
SupportingStrongThe FDA restricted Avandia in September 2010, limiting it to patients already taking the drug who could not control their diabetes with other available medications. New prescriptions effectively ended. The FDA also required a Risk Evaluation and Mitigation Strategy.
EMA suspended Avandia in Europe (September 2010)
SupportingStrongThe European Medicines Agency suspended the marketing authorisation for rosiglitazone-containing medicines in Europe in September 2010, concluding that the cardiovascular risks outweighed the benefits.
DOJ $3 billion settlement (2012) — then-largest healthcare fraud settlement
SupportingStrongGSK agreed to a $3 billion settlement with the US Department of Justice in July 2012, covering Avandia safety data concealment, unlawful promotion, and kickbacks to physicians. The settlement included criminal misdemeanour guilty pleas and was the largest healthcare fraud settlement in US history at the time.
Senate Finance Committee Found GSK Suppressed Adverse Data
SupportingStrongA 2010 bipartisan Senate Finance Committee investigation concluded that GlaxoSmithKline possessed internal analyses showing elevated cardiovascular risk from Avandia years before public disclosure. The report documented deliberate strategies to minimise, counter, and suppress publication of unfavourable trial data.
Counter-Evidence3
FDA reversed Avandia restrictions in 2013 after RECORD re-analysis
DebunkingIn 2013, the FDA lifted restrictions on Avandia after a re-analysis of the RECORD trial data by an independent committee found lower cardiovascular risk than earlier estimates. This reversal generated scientific controversy and does not undo the finding of prior non-disclosure.
Rebuttal
The 2013 restrictions reversal reflects a reassessment of the magnitude of risk, not an exoneration of GSK's conduct in failing to disclose its internal 2006 analysis. The non-disclosure to the FDA is documented and was not rebutted by the RECORD re-analysis.
Avandia did improve glycaemic control in Type 2 diabetes
DebunkingWeakAvandia was a genuinely effective drug for improving blood glucose control in Type 2 diabetes patients. Its efficacy as a glucose-lowering agent is not disputed. The controversy is about cardiovascular risk concealment, not the drug's primary pharmacological action.
Rebuttal
Therapeutic efficacy does not justify concealment of safety risk. Patients and physicians needed balanced information about both the glucose benefit and the cardiovascular risk to make informed treatment choices.
RECORD Trial Partially Redeemed Avandia's Safety Profile
DebunkingThe RECORD randomised controlled trial (2009, New England Journal of Medicine) found no statistically significant increase in cardiovascular death or myocardial infarction compared to standard therapy. FDA reviewers cited RECORD as evidence that initial meta-analysis risk estimates were overstated, complicating a simple suppression narrative.
Neutral / Ambiguous1
FDA Advisory Panel Vote Reflected Genuine Scientific Uncertainty
NeutralIn 2010 an FDA advisory panel voted 20-12 that Avandia should remain available with restrictions rather than be withdrawn entirely, reflecting contested evidence rather than clear-cut harm. The split vote indicates legitimate scientific disagreement rather than pure regulatory capture.
Timeline
Nissen NEJM meta-analysis: 43% elevated MI risk
Cardiologist Steven Nissen publishes a 42-trial meta-analysis in the NEJM showing Avandia is associated with a 43% increased risk of myocardial infarction. The publication triggers immediate FDA advisory committee review and European regulatory scrutiny.
Source →Nissen Meta-Analysis Published in NEJM
Cardiologist Steven Nissen published a landmark meta-analysis in the New England Journal of Medicine estimating a 43% relative increase in myocardial infarction risk for Avandia users. The paper triggered congressional inquiries and an FDA safety review that ultimately restricted prescribing.
Source →Senate Finance Committee: GSK had 2006 internal analysis, never disclosed
The Senate Finance Committee concludes its investigation, finding that GSK possessed an internal 2006 meta-analysis with similar cardiovascular risk findings to Nissen's — completed a year before Nissen's publication — and did not submit it to the FDA.
Source →FDA restricts Avandia; EMA suspends it in Europe
The FDA restricts Avandia to existing patients who cannot be managed with other drugs. The European Medicines Agency suspends marketing authorisation across Europe on the same day. New prescriptions effectively end in both markets.
Source →
Verdict
Senate Finance Committee (February 2010) found GSK had internal cardiovascular risk data on Avandia from 1999 onward, including an internal 2006 meta-analysis that preceded Nissen's NEJM publication by a year, and did not disclose it to the FDA. Nissen NEJM 2007: 43% increased MI risk (42-trial meta-analysis). FDA restricted Avandia in 2010. European Medicines Agency suspended it in 2010. DOJ $3 billion settlement (2012, then-largest healthcare fraud settlement in US history) covered Avandia safety data concealment and unlawful promotion.
Frequently Asked Questions
What did the Nissen meta-analysis find?
Dr. Steven Nissen's 2007 NEJM meta-analysis pooled data from 42 randomised clinical trials and found that patients taking Avandia had a statistically significant 43% higher risk of myocardial infarction compared with control groups. The cardiovascular death increase was 64% but did not reach conventional statistical significance. The analysis triggered immediate regulatory reviews in the US and Europe.
What did GSK conceal and for how long?
The Senate Finance Committee investigation found that GSK possessed internal data suggesting cardiovascular concern in Avandia as early as 1999 (the approval year) and completed an internal meta-analysis in 2006 showing similar risk to Nissen's — but did not disclose it to the FDA. If the Senate findings are accurate, the concealment period spanned approximately 8 to 11 years from early data through the 2010 restrictions.
Why was Avandia's restriction later reversed?
In 2013, the FDA lifted restrictions on Avandia after an independent committee re-analysed the RECORD trial data and concluded the cardiovascular risk was lower than previously estimated. This reversal was scientifically controversial. It reflects a reassessment of risk magnitude, not an exoneration of GSK's prior non-disclosure conduct, which was covered by the 2012 DOJ settlement.
How large was the GSK settlement and what did it cover?
The $3 billion DOJ settlement agreed in July 2012 was the largest healthcare fraud settlement in US history at the time. It covered three main areas: failure to disclose Avandia cardiovascular safety data to the FDA; unlawful promotion of Avandia and other drugs for unapproved uses; and kickback payments to physicians. GSK entered criminal guilty pleas as part of the agreement.
Sources
Show 6 more sources
Further Reading
- paperRosiglitazone and cardiovascular events — NEJM meta-analysis — Nissen SE, Wolski K (2007)
- paperSenate Finance Committee: GSK and Avandia (full report) — Senators Baucus and Grassley (2010)
- paperGSK DOJ settlement agreement and statement of facts — US Department of Justice (2012)
- bookThe Truth About the Drug Companies: How They Deceive Us and What to Do About It — Marcia Angell (2004)